NCT05504356

Brief Summary

VIBRANT-AF seeks to:

  • Identify clinically relevant predictors of effectiveness and complications of AF ablation procedures in a prospective, US-based, multi-center, real-world longitudinal study
  • Assess changes in modifiable lifestyle-related exposures influence the effectiveness of AF ablation
  • Determine incidence and predictors of complications of AF ablation procedures Participants will connect with the Eureka Research Platform and answer a series of surveys and activities over a one-year period. They will be asked about lifestyle habits, recurrence of AFib, hospitalizations, and general feelings and emotions.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,125

participants targeted

Target at P75+ for all trials

Timeline
15mo left

Started Apr 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress77%
Apr 2022Jul 2027

Study Start

First participant enrolled

April 27, 2022

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 15, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 17, 2022

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2027

Last Updated

January 23, 2026

Status Verified

January 1, 2026

Enrollment Period

4.3 years

First QC Date

August 15, 2022

Last Update Submit

January 21, 2026

Conditions

Atrial Fibrillation

Outcome Measures

Primary Outcomes (1)

  • Time to Atrial Fibrillation Recurrence

    Time to atrial fibrillation, after employing a 3-month blanking period. Atrial Fibrillation Recurrence includes patient-reported symptoms of AF or Kardia-based ECG evidence of AF.

    1 year

Secondary Outcomes (1)

  • Mean Change in the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) Score

    6 months, 1 year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects with a diagnosis of AF (i.e. new onset AF, paroxysmal AF, persistent AF, Permanent AF), who have recently or will imminently be undergoing AF ablation. Subjects will be at least 18 years of age or older, and be English-speakers, as well as adhere to the inclusion criteria pertaining to access to the Eureka mobile app (owning a smartphone device and cell phone number, email address)

You may qualify if:

  • Adults age 18 and older
  • Must have a smartphone device (iOS and/or Android) and cell phone number to participate on the mobile app, and will be willing to download the Eureka Research Platform mobile application
  • Must have email address to participate on the web portal (accessible on any web-connected device)
  • Undergone a catheter ablation procedure for atrial fibrillation in the week prior to recruitment, or have an ablation planned for within a week from recruitment

You may not qualify if:

  • Unable to consent for themselves
  • Unable to read, speak, comprehend English

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94143, United States

RECRUITING

Related Publications (1)

  • Elias A, Holtzman JN, Djomaleu ML, Freeman JV, Natale A, Hsu JC, Tzou WS, Garg L, Dukes JW, Cooper DH, Gionfriddo W, Whitman IR, Isakadze N, Spragg DD, Satti DI, Rosenthal DG, Riles EM, Hills MT, McCall D, Montenegro GC, Oo HH, Lowe DA, Gerstenfeld EP, Moss JD, Dewland TA, Hsia HH, Lee RJ, Tseng ZH, Vedantham V, Marcus GM. Feasibility of Self-Reported Surveillance After Catheter Ablation for Atrial Fibrillation Using A Mobile Application. JACC Adv. 2026 Mar;5(3):102625. doi: 10.1016/j.jacadv.2026.102625.

    PMID: 41906612DERIVED

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Gregory Marcus, MD, MAS

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Bella Peña, BA

CONTACT

415-502-3053bella.pena@ucsf.edu

Hannah Oo, BS

CONTACT

415-476-4999hannah.oo@ucsf.edu

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 15, 2022

First Posted

August 17, 2022

Study Start

April 27, 2022

Primary Completion (Estimated)

July 31, 2026

Study Completion (Estimated)

July 31, 2027

Last Updated

January 23, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations

US(1)